Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again

The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.

The reimbursement committee under the Danish Medicines Agency has recommended that Novo Nordisk’s obesity drug Wegovy is not granted general conditional reimbursement. This is the second time that the council has taken this stance.

The reasoning behind the ruling is that the committee does not consider Wegovy’s price to match its effects, and that Wegovy has not been shown to provide long-term weight loss.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs